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Abstract
Objective—There is increasing evidence that variation in gene copy number (CN) influences
clinical phenotype. The low-affinity Fcγ receptor 3B (FCGR3B) located in the FCGR gene cluster
is a CN polymorphic gene involved in the recruitment to sites of inflammation and activation of
polymorphonuclear neutrophils (PMNs). Given recent evidence that low FCGR3B CN is a risk
factor for systemic but not organ-specific autoimmune disease and the potential importance of
PMN in the pathophysiology of rheumatoid arthritis (RA), the authors hypothesised that FCGR3B
gene dosage influences susceptibility to RA.
Methods—FCGR3B CN was measured in 643 cases of RA and 461 controls from New Zealand
(NZ), with follow-up analysis in 768 cases and 702 controls from the Netherlands and 250 cases
and 211 controls from the UK. All subjects were of Caucasian ancestry.
Results—Significant evidence for an association between CN <2 and RA was observed in the
Dutch cohort (OR 2.01 (95% CI 1.37 to 2.94), p=3×10–4) but not in the two smaller cohorts (OR
1.45 (95% CI 0.92 to 2.26), p=0.11 and OR 1.33 (95% CI 0.58 to 3.02), p=0.50 for the NZ and
UK populations, respectively). The association was evident in a meta-analysis which included a
previously published Caucasian sample set (OR 1.67 (95% CI 1.28 to 2.17), p=1.2×10–4).
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Conclusions—One possible mechanism to explain the association between reduced FCGR3B
CN and RA is the reduced clearance of immune complex during infl ammation. However, it is not
known whether the association between RA and FCGR3B CN is aetiological or acts as a proxy
marker for another biologically relevant variant. More detailed examination of genetic variation
within the FCGR gene cluster is required.
INTRODUCTION
Copy number variation (CNV) in immune-response genes has been implicated in several
autoimmune diseases including CCL3L1 involvement in rheumatoid arthritis (RA)1 and
systemic lupus erythematosus (SLE),2 and association of β-defensins with Crohn’s disease3
and psoriasis.4 Recently, CNV in the gene coding for the Fcγ receptor 3B (FCGR3B), the
most abundant neutrophil binding site for polymeric IgG and immune complexes, has also
been shown to be associated with immune-mediated glomerulonephritis,5 SLE67 and, albeit
with a conflicting nature of association, antineutrophil cytoplasmic antibody (ANCA)-
associated vasculitis: CN <2 as risk factor6 or CN >2 as risk factor.7
The Fcγ receptor IIIb is constitutively expressed by polymorphonuclear leucocytes8 and is
involved in many critical neutrophil functions including recruitment to sites of
inflammation910 and activation.11 In addition, anti-FcγRIIIb antibodies and soluble
FcγRIIIb (released from apoptotic polymorphonuclear neutrophils (PMNs) or shed from
activated PMNs by cleavage of the glycosylphosphatidylinositol anchor) delay neutrophil
apoptosis1213 and may compete with IgG for binding sites to perpetuate local
inflammation.12 The presence of autoantibodies and accumulation of activated neutrophils at
sites of inflammation is a feature of RA and SLE, and there is evidence that these cells are
functionally abnormal. For example, extended survival of PMN is observed in RA and SLE,
which may reflect dysregulation of apoptosis, a major mechanism by which the activity of
neutrophils is controlled.14 The pathogenesis of RA is mediated in part by PMN, which
compose 80–90% of the cellular infiltrate during active RA.15–17 In addition to releasing
proinflammatory cytokines including tumour necrosis factor (TNF), activated PMN produce
large amounts of potentially damaging reactive oxygen species (ROS) (O2, H2O2 and
HOCL) and granular enzymes such as proteases and permeability-inducing factors, all of
which potentially contribute to tissue damage and joint erosion (see Edwards and Hallett17
for review). FcγRIIIb has been implicated in the release of these toxic products in response
to soluble immune complexes such as those found in RA joints.11 Genetic variation other
than CN variants in the FCGR locus has already been associated with RA.18 Furthermore,
FcγR-mediated production of ROS and apoptosis is impaired in PMN isolated from patients
with RA.1119
There is clinical evidence implicating FcγR in the pathogenesis of RA,14–16 association of a
haplotype encompassing FCGR3B with RA,20 and association of FCGR3B CN with SLE
and other systemic but not organ-specific immune-mediated pathology.5–7 RA is a disease
with both organ-specific and non-specific features which primarily affects the synovial
membrane but also involves a number of other tissues. On this basis, we hypothesised that
FCGR3B CN plays a role in the pathogenesis of RA. This was tested in a multicentre study
by measuring FCGR3B CN in three Caucasian RA case–control cohorts.
METHODS
Study subjects
All study subjects were of European Caucasian descent. The New Zealand (NZ) RA cohort
consisted of 643 patients recruited from outpatient clinics in Auckland, Bay of Plenty,
Wellington, Canterbury, Otago and Southland in NZ. The control group (n=461) consisted
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of healthy subjects recruited from Otago. The UK RA cohort consisted of 250 patients with
RA recruited at Lewisham and Guy’s and St Thomas’ Hospitals. One hundred and fifty-nine
UK controls were purchased from the European Collection of Cell Cultures (ECACC)
(http://www.hpacultures.org.uk/collections/ecacc.jsp) and genotyped by us, with the data
augmented by a further 52 ECACC control samples genotyped by Hollox et al.21 The Dutch
cases (n=768) were recruited from the central and eastern regions of the Netherlands.2223
These were compared to 702 controls recruited from blood donor centres within Utrecht and
Amsterdam. All the patients with RA were diagnosed according to the 1987 American
College of Rheumatology criteria for RA.24 Demographic and clinical information on the
cases and controls is given in table 1.
For the NZ and Netherlands cohorts and the UK case cohort, DNA was prepared from whole
blood by chloroform extraction. The ECACC genomic DNA was derived from
lymphoblastoid cell lines. Recruitment and DNA extraction occurred over a period of more
than 5 years for the NZ samples, whereas DNA extraction occurred over a period of less
than 2 years for the Dutch samples and UK case samples. All TaqMan Real-Time PCR was
done at the University of Otago in NZ. This necessitated shipping dried samples from the
UK and the Netherlands to NZ where they were subsequently resuspended. All aqueous
DNA was stored suspended in Tris-EDTA at −20°C.
Each of the three sample sets had ≥95% power (α=0.05) to detect an effect equivalent to that
reported for FCGR3B CN <2 in SLE in a UK sample set (OR 2.21).6 At lower effect sizes,
power decreased (eg, at OR 1.5 the power was 75% in the NZ sample set, 86% in the
Netherlands sample set and 41% in the UK sample set). The combined sample set, however,
was adequately powered to detect effects >1.3 (79% power at OR 1.3).
Measurement of FCGR3B CN
At the FCGR3 locus there are two patterns of CNV that include FCGR3B25—the major one
also encompasses FCGR2C and the minor one also encompasses HSPA7/FCGR2C/
FCGR3A/HSPA6 (deviation from CN=2 present in 11.2% and 0.8%, respectively, of a
healthy sample set from the Netherlands25). The exact boundaries of CNV are not known.
FCGR3B CN was measured using TaqMan Real-Time PCR, as described in the online
supplement, using an assay based on one previously described for CCL3L1.26 Variations in
DNA quality increase the ‘noise’ of the assay system,21 which can prevent clear clustering
of continuous values around whole integers and poor quality DNA increases the risk of false
positive results.27 All NZ and Netherlands case genomic DNA samples were
electrophoresed on an agarose gel and integrity scored from 1 (single high molecular weight
band) to 4 (most degraded). Samples with scores of 3 and 4 were discarded from analysis.
This was not done for the Netherlands control samples because they exhibited discrete CN
bins (see fig 4 in online supplement), suggesting no blurring of CN calls owing to DNA
degradation.27 Insufficient genomic DNA was available for the UK samples to enable
testing by agarose gel. To minimise DNA degradation, NZ samples were freshly diluted
from 200 μg/ml stock and used within 2 weeks.
Assignation of FCGR3B CN
In order to compensate for differences in mean and variance distribution between cases and
controls, the a posteriori model fitting CNVtools algorithm28 was used to determine the cut-
off CN value between 1 and 2 for each sample set and CN was assigned as described in
more detail in the online supplement.
As additional evaluations of the qPCR assay, 72 NZ controls were first analysed by
paralogue ratio testing (PRT)/restriction enzyme digest variant ratio using a previously
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developed and validated assay.21 Our data demonstrated good agreement between PRT
(which has a first-pass error rate of 8%29) and TaqMan assays within the range of 1–3
copies (see table 2 in online supplement), and there was strong agreement between the
assigned NA type by both methods. Eight of the PRT results differed by one copy compared
with CNVtools assignment, with the PRT value uncertain for one of the differences. We
then compared genotypes between the 30 overlapping UK ECACC controls genotyped by us
and by Hollox et al21 (see table 3 in online supplement) and achieved 100% concordance in
CN assignment.
Association analysis
The distributions of FCGR3B CN between patients and controls after CN assignment by
CNVtools were compared using the χ2 test. Logistic regression analysis was used to
measure the RA-associated risks of low FCGR3B CN as the OR relative to CN ≥2 using the
STATA 7.0 statistical package (StataCorp, College Station, Texas, USA). Because a mixture
of CNVtools fitting models28 were needed for our cohorts, combined (meta-) analysis of all
three cohorts was performed using the Mantel–Haenszel test, comparing CN <2 to ≥2 after
testing for heterogeneity by the Breslow–Day test.
RESULTS
The distribution of FCGR3B CN as a continuous variable is shown in figure 1. CN
assignment showed that 93.6% of the combined control cohort had two or more copies of
FCGR3B and 6.4% carried single copy deletions (table 2). No control individuals lacked
both alleles. One patient in each of the Dutch and NZ case cohorts had a null FCGR3B
genotype. The FCGR3B CN allele distribution among our controls was very similar to that
observed previously based on measurement by the multiplex ligand-dependent probe
amplification technique in a cohort of 129 healthy individuals of Northern European
ancestry (CN 0, 0%; 1, 7%; 2, 83%; 3, 10%),24 and similar to that observed using an
integrated ;approach in UK samples (CN 0, 0%; CN 1, 4%; 2, 87%; >3, 9%).21
To test the hypothesis that FCGR3B CN influences susceptibility to RA, the influence on
disease risk of CN <2 of FCGR3B was tested under the prediction that any association of
FCGR3B with RA would be similar to that evident in SLE where CN <2 increases the risk
of disease by slowing the rate of immune complex clearance during transient
inflammation.5–7 Table 2 shows the disease risk for CN 0–1 relative to CN ≥2. Significant
evidence for an association between CN <2 and RA was observed in the Dutch cohort (OR
2.01 (95% CI 1.37 to 2.94), p=3×10−4) but not in the two smaller cohorts (OR 1.45 (95% CI
0.92 to 2.26), p=0.11 and OR 1.33 (95% CI 0.58 to 3.02), p=0.50 for the NZ and UK
populations, respectively). In a combined (meta) analysis that included previously published
data from a small case–control sample set of Northern European ancestry (table 2; OR 1.31
(95% CI 0.51 to 3.34)), there was strong evidence for CN <2 FCGR3B increasing the risk of
disease (figure 2; OR 1.67 (95% CI 1.28 to 2.17), p=1.2×10−4).
Given that rheumatoid factor (RF) is an anti-FCG, we tested for an association between
FCGR3B CN and the presence or absence of RF (table 3). There was some evidence for an
association of low CN with RF-negative RA in the NZ and UK cohorts (p=0.08 and p=0.02,
respectively), but not in the Dutch cohort (p=0.69). In the combined cohorts there was no
evidence for differential association between FCGR3B CN <2 and RF status, nor was there
any evidence for an association between NA type and RA for NZ and UK samples with CN
1 or 2 (see table 4 in online supplement).
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DISCUSSION
Our results provide evidence that CNV in FCGR3B is associated with RA (combined
analysis of four Caucasian RA case–control sample sets: OR 1.67 (95% CI 1.28 to 2.17),
p=1.2×10−4). While only the largest sample set exhibited a significant association with RA,
the other three included in the meta-analysis consistently showed an increased risk for RA
(OR >1) in the presence of FCGR3B deletion, and there was no significant intercohort
heterogeneity (table 2; p=0.60, Breslow–Day). While the ANCA-associated systemic
vasculitis data require further clarification,67 our results are consistent with previous reports
of an association between low CN and systemic autoimmunity in other diseases including
glomerulonephritis and SLE.5–7 This suggests a common pathogenic role for FCGR3B (or
an associated variant in the FCGR locus) in systemic autoimmune diseases.
Confirmed genetic associations have defined aberration in the activation, regulation and
migration of T cells as central to the aetiology of RA in Caucasian populations, including
HLA-DRB1,30 protein tyrosine phosphatase N22,31 a locus near the TNF-induced protein 3
gene,3233 the signal transducer and activator of transcription 4 gene,34 a locus between the
TNF receptor-associated factor 1 and C5 genes3536 and the CD40, chemokine ligand 21,
CD122, KIF5A and protein kinase chloroquine genes.3738 The association of FCGR3B CN
with RA reported here still requires further replication in other populations before it can be
considered confirmed. Nonetheless, if this association is validated, it would implicate
genetic regulation of immune complex deposition and clearance in the pathophysiology of
RA. Although there was no association between FCGR3B CN and RF status, we had no
information on the presence or absence of anti-cyclic citrullinated peptides (anti-CCPs) in
all of our populations and therefore could not analyse the relationship between anti-CCP and
FCGR3B CN. Antibodies to citrullinated proteins are now considered a more specific
marker of disease than RF status,39 and although there is a large overlap between anti-CCP
and the presence/absence of RF, it is possible that FCGR3B deletion is more strongly
associated with anti-CCP negative RA. This needs to be addressed in future studies.
Although quantitative PCR (qPCR) has been a popular method for measuring CNV owing to
suitability for genotyping a large number of samples, and is a relatively accurate method of
detecting single-copy deletions and duplications,29 there are a number of factors that can
influence the accuracy of assays. Because CN is measured relative to a reference gene,
variation in amplification efficiency and experimental conditions can alter the ratio of the
two products and thus apparent CN.28 DNA quality also influences assay efficiency and can
introduce false positives and batch effects when comparing cohorts collected and stored
under different conditions.2728 Because the CN values are (rarely) integer values, arbitrary
‘binning’ of samples to whole numbers can introduce false associations if the distribution of
two populations differs in mean and/or variance.28 To compensate for batch effects and
systematic errors, cases and controls were assayed concurrently. The modelling algorithm
CNVtools was used to determine the cut-off between CNs 1 and 2 and those with values
±0.05 of the cut-off between CNs 1 and 2 were removed. Independent verification of the
qPCR technique was carried out using PRT (see Materials and methods). Because degraded
DNA samples can yield spurious CNV results,27 samples exhibiting excessive degradation
were removed from analysis in this study.
Genotyping within the FCGR locus is a complex undertaking owing to the extensive
homology that exists between the FCGR genes. Because there is FCGR3B duplication and
deletion on multiple haplotypes,2125 there are no known single nucleotide polymorphisms
(SNPs) that can be used to accurately predict CN.21 A major conclusion from the
comprehensive analysis of the FCGR locus by Hollox et al21 was that direct measurement of
CN by an integrated suite of methods combined with association analysis of SNPs is
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required to fully evaluate the contribution of FCGR3B to RA. Here we focused on direct
measurement of FCGR3B CN by a single method (TaqMan) that is suited to larger-scale
genotyping. Future work on this locus in RA should include data on association of SNP
haplotypes.
FCGR3B CN correlates with the level of receptor expression (both surface and soluble
forms), neutrophil adherence to IgG and internalisation of opsonised particles.7 While our
results appear counterintuitive to the possibility that FcγRIIIB deletion has a role in RA
through this process, they highlight the fact that the differential roles of PMN activation and
immune complex clearance in the immune response (and the exact function of FcγRIIIB)
require further investigation. It is also relevant to emphasise that our data are consistent with
the findings observed in SLE.67 There are at least three possible explanations for how
reduced FcγRIIIb levels could increase the risk of RA.
First, FcγRIIIb can bind intravascular immune complexes in the absence of any other
inflammatory mediators but fails to generate ROS, whereas FcγRIIa (predominantly
expressed by macrophages and natural killer (NK) cells) is responsible for ROS-mediated
tissue damage.40 The reduced adherence and phagocytic capabilities of PMN in the case of
low FCGR3B CN may delay clearance of immune complexes during episodes of transient
inflammation and prolong the inflammatory response either to initial joint damage or to an
exogenous infection that subsequently triggers an autoimmune response. This would allow
the development of an inflammatory milieu where FcγRIIa activity predominates, as has
been suggested for glomerulonephritis and SLE.6741
Second, changes in FCGR3B CN may alter PMN function indirectly by shifting the balance
of activating receptors and potentially ‘unmasking’ the effects of functional polymorphisms
in other FCG receptors. Furthermore, PMN are an important source of proinflammatory
chemokines, which are partly mediated through FcγRIIa and FcγRIIIa.8 Both are FCG
receptors that have been implicated in RA and SLE.41
A third possibility is that the increased susceptibility to RA associated with low FCGR3B
CN is due not to reduced FCGR3B dosage but to deletion in FCGR2C, since CNV in these
two genes is strongly related.2542 FcγRIIc is expressed on macrophages, PMN43 and NK
cells44 where it triggers antibody-dependent cellular toxicity (ADCC).45 ADCC may play an
important role in regulating autoimmune responses by lysing autologous immature dendritic
cells.4546 Defective NK cell cytotoxicity has been reported in a number of autoimmune
disorders including RA, juvenile RA, SLE and macrophage activation syndrome.4748 An
SNP within exon 5 of FCGR2C is functionally equivalent to a deletion of the gene. The null
allele of this polymorphism occurs more often in patients with RA than in controls and
results in an apparent shift towards increased expression of the inhibitory FcγRIIb.49
Whether this is also the case in the context of FCGR3B/FCGR2C deletion is unknown. It
should be noted that rare (~1%) deletion events encompassing FCGR3B/FCGR2C/FCGR3A
have been observed in Caucasian populations.25
In this paper we provide evidence for an association between a low FCGR3B CN and
susceptibility to RA. Whether this is due to biological effects of FcγRIIIb itself or is a proxy
marker for another biologically relevant polymorphism will require further study, validation
in other sample sets and better characterisation of structural variation within the FCGR
locus.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Distribution of Fcγ receptor 3B copy number (CN) as a continuous variable in the three case
and control cohorts. Data are shown without removal of samples. Boxes and lines
encompass samples within 1 and 2 SD from the mean, respectively. Mean (SD) values for
the six sample sets are (from left to right): 2.23 (0.45), 2.04 (0.39), 2.18 (0.25), 1.89 (0.20),
2.14 (0.24) and 1.92 (0.26).
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Figure 2.
Meta-analysis of the association between low Fcγ receptor 3B (FCGR3B) copy number and
rheumatoid arthritis for the four sample sets using Metan (STATA Version 7.0) with a fixed
Mantel–Haenszel pooling model. FCGR3B CN of 0–1 was designated as the minor allele
and copy number ≥2 as the major allele.
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Table 1
Demographic and clinical characteristics
Age (mean,
range, N*)
Women
% (N)
RF
% (N)
CCP
% (N)
SE positivity
% (N)
New Zealand
 Cases 65.5, 20–88, 351† 78.8 (643) 82.3 (560) 67.0 (367) 80.1 (626)
 Controls 44.6, 17–95, 461† 61.2 (461) – – –
UK
 Cases NA 79.3 (241) 63.1 (241) NA 79.1 (239)
 Controls NA NA – – –
The Netherlands
 Cases 48.7, 4–79, 578‡ 65.5 (586) 78.5 (685) NA NA
 Controls NA 49.2 (702) – – –
*N is the number of individuals from which data were available.
†Age at recruitment.
‡Age at disease onset.
CCP, cyclic citrullinated peptide; NA, not available; RF, rheumatoid factor.
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Table 2
Fcγ receptor 3B (FCGR3B) copy number (CN) and risk for rheumatoid arthritis (RA)
FCGR3B CN Cases, N (frequency) Controls, N (frequency) OR (95% CI) p Value
New Zealand RA <2 60 (0.099) 32 (0.071) 1.45 (0.92 to 2.26) 0.11
≥2 546 (0.901) 421 (0.929) 1.00
UK RA <2 15 (0.062) 10 (0.047) 1.33 (0.58 to 3.02) 0.50
≥2 228 (0.938) 202 (0.953) 1.00
Dutch RA <2 86 (0.116) 43 (0.061) 2.01 (1.37 to 2.94) 3.0×10−4
≥2 655 (0.884) 658 (0.939) 1.00
Breunis RA25 <2 10 (0.089) 9 (0.070) 1.31 (0.51 to 3.34) 0.57
≥2 102 (0.901) 120 (0.930) 1.00
Combined RA* <2 171 (0.100) 94 (0.063) 1.67 (1.28 to 2.17) 1.2×10−4
≥2 1531 (0.900) 1401 (0.937) 1.00
*p=0.60, Breslow–Day.
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Table 3
Fcγ receptor 3B (FCGR3B) distribution in rheumatoid factor (RF) positive and negative patients
FCGR3B CN RF negative,N (frequency)
RF positive,
N (frequency) OR (95% CI) p Value
New Zealand (RA) <2 14 (0.156) 41 (0.094) 0.56 (0.29 to 1.08) 0.08
2 76 (0.844) 396 (0.896) 1.00
UK RA <2 10 (0.115) 5 (0.034) 0.27 (0.09 to 0.82) 0.02
2 77 (0.885) 142 (0.966) 1.00
Dutch RA <2 16 (0.112) 64 (0.124) 1.13 (0.63 to 2.02) 0.69
2 127 (0.888) 451 (0.876) 1.00
Combined RA* <2 40 (0.125) 110 (0.100) 0.78 (0.53 to 1.14) 0.20
2 280 (0.875) 989 (0.900) 1.00
*p=0.055, Breslow–Day.
CN, copy number; RA, rheumatoid arthritis.
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